Vomiting, diarrhea, and other gastrointestinal signs are among the most common reasons for a dog to require a visit to the veterinarian. Ascertaining the cause of these signs is often a time-consuming task for clinicians and a frustrating and expensive process for pet owners, especially in the case of a complex condition like chronic enteropathy (commonly referred to as inflammatory bowel disease).
The CE-IBD Assay uses three individual biomarkers in combination to provide a result of consistent or not consistent with chronic enteropathy. Trending the results of the individual biomarkers can be useful in monitoring response to therapy.
The CE-IBD Assay has value when patients are on a therapeutic dietary trial, antibiotics, corticosteroids, and other immunosuppressive agents.
Available exclusively through Antech, RenalTech™ is a breakthrough in predictive medicine. Powered by artificial intelligence, RenalTech™ uses common serum and urine diagnostics to predict whether a cat will develop chronic kidney disease in the next two years—with greater than 95% accuracy.
Rapid access to effective treatment for CE/IBD is the goal. It’s also essential as the disease can have a serious impact on a dog’s health and overall well-being. An affected dog generally experiences vomiting and/or diarrhea, poor appetite, weight loss, flatulence and abdominal discomfort for approximately at least 3 weeks before CE/IBD can be ruled in with certainty, though many practitioners may begin to suspect the condition earlier based on clinical experience.